Engen Is An Early Stagebiotechnology Company Pioneering A New Approach To Preventing And Treating Influenzaweredeveloping An Effectiveeasy To Manufactureshelf Stableuniversal Flu Vaccinethat Confers Long Term Immunity To All Typea Influenza Strainsae Including Thosewhich Causeseasonal Flu And Influenza Pandemics Seasonal Flu Causes 250 000 To 500 000 Deaths Every Yearthecdc And Other Experts Havecautioned That Weareextremely Vulnerableto Thecatastrophic Occurrenceof A Global Flu Pandemicae On A Scalethat Could Far Exceed Both Covid 19 And Thespanish Flu Of 1918In Its Global Influenza Strategy2019Ae20 0Reporttheworld Health Organization Has Declared Thedevelopment Of A Universal Flu Vaccineas An Urgent Needae But Theuniquenatureand Genetic Makeup Of Theinfluenza Virus Poses A Challengeto Researchers Focused On Influenza Treatment And Vaccinationto Address Theseissuesengen Bio Is Developing Universal Vaccines For Typea Flu Preventioneffectivefor Vaccination In Both The$6B Human And $0 5B Veterinary Marketsour Antibodies Also Demonstratepotential For Therapeutic Treatment Of Influenzawith An Additional $2B Prospectivemarketif Successfulour Efforts Will Eradicateflu Pandemics And Dramatically Decreasetheglobal Burden Of Illness And Diseasecaused By Influenza
